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ABSTRACT 19 
Aquaporin-1 (AQP1) is a homo-tetrameric transmembrane protein that facilitates rapid 20 
movement of water and ions across cell membranes. The clinical significance of AQP1 21 
expression in colorectal carcinoma (CRC) is controversial. The aim of this study was to 22 
investigate the prognostic significance of AQP1 transcript expression and the association 23 
between expression and promoter methylation in normal colonic mucosa, CRC tissues and 24 
cell lines. Analysis of publicly available datasets from The Cancer Genome Atlas revealed 25 
that AQP1 expression was significantly decreased in CRC compared to normal mucosa (12.7 26 
versus 33.3 respectively, P < 0.0001). However, expression increased with advanced disease, 27 
being significantly higher in stage IV (17.6) compared to either stage I (11.8, P = 0.0039) or 28 
II (10.9; P = 0.0023), and in patients with lymph node metastasis compared to those without 29 
(13.9 versus 11.3 respectively, P = 0.0023). Elevated expression was associated with 30 
decreased overall survival with univariate (Cox Proportional Hazard Ratio 1.60, 95% 31 
confidence interval 1.05-2.42, P = 0.028), but not multivariable analysis when considering 32 
the confounders stage and age. Analysis of HumanMethylation450 data demonstrated that 33 
AQP1 promoter methylation was significantly increased in CRC compared to normal 34 
mucosa. Analysis of CRC tissues and cell lines strongly suggested that methylation was 35 
associated with decreased expression. BRAFV600E mutation alone did not explain the increase 36 
in methylation. In conclusion, AQP1 transcript expression was decreased in CRC compared 37 
to normal mucosa, and this was associated with AQP1 promoter hypermethylation. AQP1 38 








Globally, colorectal carcinoma (CRC) is one of the most commonly diagnosed cancers and is 46 
a leading cause of cancer-related deaths [1]. At diagnosis, up to 25% of patients present with 47 
metastatic disease (stage IV). Additionally, up to 25% of patients diagnosed with early 48 
localised disease (stage I or II) and 50% with locally advanced CRC (stage III) eventually 49 
relapse with overt metastatic disease following surgery with curative intent [2]. Despite 50 
recent advances in treatment, patients with metastatic disease currently have 5-year survival 51 
rates of less than 15%, and a median overall survival of approximately 30 months [3, 4]. 52 
There is a need to improve staging and treatment of CRC. 53 
 54 
Aquaporin-1 (AQP1) forms a homo-tetrameric transmembrane channel that facilitates the 55 
rapid movement of water and ions across cell membranes in response to osmotic gradients 56 
[5]. Increased expression has been reported in numerous cancer types including brain, breast, 57 
cervical, lung, renal, and CRC [6]. Previous studies have suggested that AQP1 is involved in 58 
enhancing cancer cell migration and invasion (reviewed in[6]). Studies comparing AQP1-null 59 
and wildtype mice suggest that AQP1 promotes tumour growth by enhancing endothelial cell 60 
migration and angiogenesis [7]. Whilst the relevance of AQP1 expression has been 61 
investigated in numerous cancer types, only a small number of studies have investigated the 62 
prognostic significance of AQP1 protein expression in CRC, and these have yielded 63 
conflicting results [8, 9, 10].  64 
 65 
Changes in DNA methylation are frequent, early events in carcinogenesis [11]. DNA 66 
methylation is of clinical interest because it might lead to biomarkers for early detection, 67 
diagnosis, prognostication, therapeutic stratification, and post-therapeutic monitoring. 68 
 4 
Promoter methylation plays a role in mediating gene expression, as evidenced by studies 69 
showing that methylation of gene promoter regions varies considerably depending on the cell 70 
type, with more methylation correlating with low or no transcription [12]. This has been 71 
highlighted in cancer, as experimentally shown by some research groups, which show that 72 
hypermethylation occurs in cancer at promoters of genes already transcriptionally 73 
repressed [13, 14]. However, studies on the association between AQP1 promoter 74 
methylation and gene expression are currently limited to glioblastoma multiform, normal 75 
salivary gland and salivary gland adenoid cystic carcinoma [15, 16, 17], and have not been 76 
reported for other carcinomas including CRC. 77 
 78 
The aim of this study was to investigate the prognostic significance of AQP1 transcript 79 
expression and the association between expression and promoter methylation in colon cancer 80 
cell lines, normal colonic mucosa and CRC tissues. 81 
 82 
RESULTS 83 
Expression of AQP1 was reduced in colorectal carcinoma compared to normal mucosa 84 
Expression of AQP1 transcript was analysed in the combined The Cancer Genome Atlas 85 
(TCGA) colon (TCGA-COAD) and rectal adenocarcinoma (TCGA-READ) datasets. 86 
Transcript expression data, reported as the median number of fragments per kilobase of exon 87 
per million reads (FPKM), were available for 590 patients with confirmed CRC, 47 of which 88 
had matched normal colonic mucosa (summary of clinicopathological features in Table S1). 89 
There was no significant difference in the median age of the 590 CRC patients (68 years, 90 
range 31-90) compared to those with normal mucosa (73 years, range 40-90; P = 0.0585). 91 
Expression of AQP1 was significantly higher in normal mucosa (median 33.3, range 11.2-92 
146.4) compared to either all CRC (median 12.7, range 0.8-175.9, P < 0.0001) or to patient 93 
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matched CRC (median 15.8, range 3.9-126.7, P < 0.0001). Expression was higher in the 94 
normal mucosa compared to CRC for 40 of 47 patients (85 %). Analysis of publicly available 95 
datasets deposited in Oncomine (www.oncomine.org) provided further supportive evidence 96 
that AQP1 transcript expression was significantly higher in normal mucosa compared to 97 
either CRC or adenoma (Table S2). Together, these data strongly suggest that AQP1 98 
transcript expression was significantly decreased in CRC compared to normal mucosa. 99 
 100 
Analysis of the TCGA datasets by disease stage revealed that expression was significantly 101 
higher in normal mucosa compared to either stage I (median 11.8, range 0.8-138.5, P < 102 
0.0001), II (median 10.9, range 2.0-126.7, P < 0.0001), III (median 13.9, range 2.2-175.9, P 103 
< 0.0001), or IV (median 17.6, range 2.0-153.7, P = 0.0003) CRC (Table 1). Expression 104 
increased with advanced stage, being significantly higher in stage IV compared to either 105 
stage I (P = 0.0039) or II (P = 0.0023), and in patients with lymph node metastasis (stage III) 106 
compared to those without (stage I-II, median 13.9, range 2.2-175.9, P = 0.0039). Expression 107 
was significantly less in right-sided compared to left-sided CRC (median 11.4, range 0.8-108 
175.9 versus median 13.4, range 2.0-153.7 respectively, P = 0.0284). It was not significantly 109 
different for gender, age, morphology, or BRAF mutation status. 110 
 111 
Reduced AQP1 expression was associated with increased overall survival in univariate but 112 
not multivariable analysis 113 
Kaplan-Meier analysis of the overall survival (OS) for the 590 patients represented in the 114 
combined TCGA datasets demonstrated that elevated AQP1 expression (defined as a FPKM 115 
≥ 11.4) was associated with significantly poorer OS (P = 0.0142; Figure 1). A subset analysis 116 
was performed on 453 of the 590 patients with complete clinical data. Elevated AQP1 117 
transcript expression was associated with poorer OS in the univariate (Table 2; hazard ratio 118 
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(HR) 1.60, 95% confidence interval (CI) 1.05-2.42, P = 0.028) but not the multivariable 119 
model (HR 1.15, 95% CI 0.75-1.77, P = 0.523). Age and stage of cancer remained 120 
significant, independent predictors of OS in the multivariable model: in summary, each 1 121 
year increase in age was associated with a 4% increase in risk of dying; when compared to 122 
patients with stage I-II cancer, the risk of dying was 2.6 times higher amongst patients with 123 
stage III and 7.66 times higher amongst those with stage IV cancer.  124 
 125 
AQP1 promoter was frequently hypermethylated in CRC compared to normal mucosa 126 
Having identified that AQP1 transcript expression was decreased in CRC compared to 127 
normal mucosa, we examined if the reduced expression was associated with AQP1 DNA 128 
methylation. Infinium HumanMethylation450 BeadChip (HM450) DNA methylation data 129 
were available for 317 of the 590 CRC patients (225 from TCGA-COAD and 92 from 130 
TCGA-READ), 32 of which had patient matched normal mucosa. Methylation data, 131 
expressed as beta-values, for AQP1 were available for 21 CpG probesets, of which 10 were 132 
located -5,000 to -1 bp upstream of the transcription start site (TSS), eight were in the gene 133 
body defined as +1 to +13,824 bp downstream of the TSS, and two were in the distal 134 
intergenic region within 10,000 bp of the end of the gene body. There were no overt 135 
differences in methylation of these probesets between colon and rectal carcinoma. 136 
Statistically significant differences in average beta-values between normal mucosa and CRC 137 
were observed for 16 of the 21 probesets (Figure 2, Figure S1 and Figure S2; Bonferroni 138 
adjusted P < 0.05). For the eight probesets located between -200 and +200 bp of the TSS the 139 
average beta-values for normal mucosa were < 0.2 and were significantly less than the 140 
average beta-values for CRC (Figure 2). Methylation was significantly higher 141 
(hypermethylated) in CRC compared to normal mucosa for all 13 probesets in the region -142 
385 to +1,653 bp of the TSS and for the probeset at -658 bp (Figure 2 and Figure S2; 143 
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Bonferroni adjusted P < 0.05). In contrast, for the 2 probesets located in the distal intergenic 144 
region, at +13,977 and +21,814 bp, methylation was significantly lower in CRC compared to 145 
normal mucosa. No significant differences were observed for the probesets at -4,832, -407, 146 
+3,051, +9,315 and +12,504 bp. Differential methylation (deltaBeta, defined as a difference 147 
in average beta-values for normal mucosa subtracted from CRC of > 0.2) was observed for 6 148 
of 18 probesets (33.3 %) located within region from -658 bp to the end of the gene body 149 
(Figure 2 and Figure S1). This data clearly demonstrates that the AQP1 promoter was 150 
hypermethylated in CRC compared to normal mucosa. 151 
 152 
Reduced AQP1 expression correlated with promoter methylation in colorectal carcinoma 153 
tissues and colon cancer cell lines 154 
We investigated if AQP1 promoter methylation was associated with decreased expression in 155 
CRC tissues and cell lines. Expression and methylation data were available for the 317 CRC 156 
samples from the combined TCGA datasets. Statistically significant inverse correlations were 157 
observed for 15 of 16 probesets located in the region -658 to +3,051 bp from the TSS (Figure 158 
S3, Bonferroni adjusted P < 0.05). When the CRC samples were stratified based on low 159 
(FPKM < 11.4) or high (FPKM ≥ 11.4) AQP1 expression, low expression was associated 160 
with significant increases in methylation for 8 of 9 probesets located in the region -90 to 161 
+3,051 bp of the TSS and for the probeset at -658 bp (Figure 3 and Figure S4; Bonferroni 162 
adjusted P < 0.05). This data suggest that AQP1 promoter methylation was associated with 163 
reduced transcript expression in CRC tissues. 164 
 165 
Next, we examined if reduced expression of AQP1 was associated with promoter methylation 166 
in colon cancer cell lines. Analysis of microarray gene expression datasets for cell lines that 167 
constitute the National Cancer Institute’s NCI60 panel, representing breast, central nervous 168 
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system, colon, leukemia, melanoma, non-small cell lung cancer, ovarian, prostate and renal 169 
tumours, revealed that typically the highest expression of AQP1 was observed in the colon 170 
cancer cell line COLO 205. Of the seven colon cancer cell lines represented in the NCI60 171 
panel, expression was relatively high in COLO 205, moderate in HT-29 and HCC2998 and 172 
low in SW620, KM12, HCT 116 and HCT 15 (Figure 4a). We independently validated these 173 
findings in COLO 205, HT-29 and HCT 116 using AQP1 TaqMan Gene Expression Assays 174 
(Figure 4b). Expression of AQP1 was significantly higher in COLO 205 compared to HT-29 175 
(P < 0.0001), and in HT-29 compared to HCT 116 (P < 0.0001). 176 
 177 
Analysis of the DNA methylation for the colon cancer cell lines stratified based on the level 178 
of AQP1 transcript expression suggested that low expression was associated with an increase 179 
in methylation for the probesets located near the TSS (Figure 4c and Figure S5; P < 0.05). 180 
Differences were observed for 5 of 10 probesets located within the promoter region between -181 
5,000 and -1 bp upstream of the TSS, and in 1 of 9 probesets in the gene body. Differential 182 
methylation (deltaBeta > 0.2) calculated by subtracting the average beta-value of the high to 183 
moderate from the low expressing cell lines was observed in 13 of 21 probesets (Figure 4c); 184 
all 10 probesets in the region from -407 to +27 bp and the three probesets in the region from 185 
+1653 to +9,315 bp.  186 
 187 
Next, we analysed the transcriptional response to the global demethylating agent 5-aza-2’-188 
deoxycytidine (5-aza-dC). Analysis of a publicly available dataset [18] demonstrated that 189 
treatment of HT-29 with 5 and 10 µM 5-aza-dC for 5 days induced significant upregulation 190 
of AQP1 transcript expression (Figure 4d; P = 0.0004 and P = 0.0171, respectively). To 191 
confirm and expand on these findings, we measured changes in AQP1 expression in COLO 192 
205, HT-29, and HCT 116, which display low, intermediate and high AQP1 promoter 193 
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methylation respectively (Figure S5), treated with 5-aza-dC (Figure 4e). Treatment of COLO 194 
205 with 1 µM resulted in a slight (1.4-fold), statistically significant increase in AQP1 195 
expression (P = 0.0031). In contrast, treatment of HT-29 and HCT 116 with either 1, 5 or 10 196 
µM aza-dC resulted in marked (> 3.6-fold for all), significant increases in AQP1 expression 197 
(P < 0.0001 for all), with the magnitude of the changes being greater in HCT 116. Together, 198 
these data provide strong evidence that reduced AQP1 transcript expression was associated 199 
with promoter hypermethylation in CRC tissues and colon cancer cell lines. 200 
 201 
The BRAFV600E mutation alone was not associated with AQP1 promoter hypermethylation  202 
The mechanisms driving aberrant AQP1 promoter hypermethylation that was observed in 203 
CRC are unknown. The BRAFV600E mutation is known to be associated with high CpG island 204 
methylator phenotype (H-CIMP) in CRC. We investigated if the BRAFV600E mutation was 205 
associated with AQP1 methylation in tissues and cell lines. Of the 317 CRC with methylation 206 
data, 275 had wildtype BRAF, 26 had a BRAFV600E mutation, and 16 had other BRAF 207 
mutations. Differential methylation (deltaBeta > 0.2) between wildtype and BRAFV600E CRC 208 
was not observed for any of the probesets (Figure 5a). Methylation was significantly greater 209 
in CRC that harboured the BRAFV600E mutation compared to wildtype for 1 of 21 probesets, 210 
located +1,653 bp from the AQP1 TSS (Figure S6; Bonferroni adjusted P < 0.05).  211 
 212 
Finally, we investigated if the BRAFV600E mutation was associated with AQP1 promoter 213 
methylation in the NCI60 cell lines. Analysis of the mutation data deposited in the Catalogue 214 
of Somatic Mutation in Cancer database (COSMIC; http://cancer.sanger.ac.uk/cosmic, [19]) 215 
demonstrated that the BRAFV600E mutation was present in two of seven colon cancer (COLO 216 
205 and HT-29) and seven of nine melanoma cell lines. Another two cell lines, the colon 217 
cancer line KM12 and the breast cancer line MDA-MB-231, had other mutations in BRAF. 218 
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One of the 60 cell lines (NCI-ADR-RES) was excluded from the analysis because it was 219 
known to be contaminated with OVCAR-8. In contrast to CRC tissues, reduced differential 220 
methylation (deltaBeta < -0.2) was observed in the cell lines with the BRAFV600E mutation 221 
compared to wildtype for 3 of 21 probesets, located at -385, -90, and -39 bp from the TSS 222 
(Figure 5b). However, differential methylation was not statistically significant for any of the 223 
21 probesets analysed (Figure S7). 224 
 225 
DISCUSSION 226 
Our analysis of publicly available datasets revealed that AQP1 transcript expression was 227 
significantly decreased in CRC compared to normal mucosa. In CRC, expression increased 228 
with advanced disease, and was associated with a significant decrease in OS with univariate 229 
but not with multivariable analysis when the confounders stage and age were considered. 230 
AQP1 promoter methylation was significantly increased in CRC compared to normal 231 
mucosa, and analysis of CRC tissues and cell lines strongly suggested that AQP1 promoter 232 
hypermethylation was associated with decreased expression. The BRAFV600E mutation alone 233 
did not explain the increase in promoter methylation. 234 
 235 
We report the novel findings that the AQP1 promoter was hypomethylated in normal colonic 236 
mucosa, hypermethylated in a significant proportion of CRC, and methylation was associated 237 
with decreased transcript expression in CRC patient tissues and colon cancer cell lines. 238 
Further, treatment of colon cancer cell lines with a global demethylating agent, 5-aza-dC, 239 
significantly increased AQP1 expression. To the best of our knowledge, regulation of AQP1 240 
expression by promoter methylation has previously only been demonstrated in 241 
glioblastoma multiform, normal salivary tissue and an adenoid cystic carcinoma cell line 242 
(SACC83), and a hypomethylated promoter was associated with a relative increase in 243 
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expression in a proportion of salivary gland adenoid cystic carcinomas [15, 16, 17]. 244 
Treatment of the SACC83 cell line with global demethylating agents, 5-aza-dC and 245 
trichostatin A, decreased AQP1 promoter methylation and upregulated expression, providing 246 
further supportive evidence that AQP1 promoter methylation was associated with a reduction 247 
in transcript expression [16]. 248 
 249 
There are limited published data comparing AQP1 expression in normal colonic mucosa to 250 
CRC. Imaizumi et al reported that AQP1 protein was not detected in the normal epithelial 251 
cells but was expressed in 112 of 268 (41.8 %) of stage 0 to IV CRC [10]. Mobasheri et al 252 
evaluated the relative abundance and distribution of AQP1 protein using 253 
immunohistochemistry and quantitative histomorphometric analysis of tissue microarrays. 254 
They reported that AQP1 was expressed in capillary endothelia of normal tissues, and 255 
expression was higher in the microvascular structures of CRC. AQP1 was observed in some 256 
neoplastic tumour cells, however they did not comment on expression in normal colonic 257 
mucosa [20]. Moon et al using in situ hybridization reported strong AQP1 transcript 258 
expression in the colon cancers and adenomas from 12 patients, with almost no expression in 259 
adjacent normal mucosa [21]. In contrast, we had previously reported using TaqMan PCR 260 
that AQP1 transcript expression was higher in patient matched normal colonic mucosa 261 
compared to CRC for 35 of 57 (61 %) patients [22]. Confirming our previous findings, we 262 
report here that AQP1 transcript expression was significantly greater in normal mucosa 263 
compared to CRC for 40 of 47 (85 %) patient matched samples available in combined TCGA 264 
datasets. Furthermore, analysis of multiple publicly available datasets in Oncomine provided 265 
further supportive evidence that transcript expression was significantly greater in normal 266 
mucosa compared to CRC. However, a limitation of these studies that assessed AQP1 267 
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transcript expression is that we cannot be certain that transcript expression was restricted to 268 
the epithelia, nor that transcript levels translated to protein expression.  269 
 270 
Previous reports found that AQP1 protein was expressed in 40-60% of CRC. Yoshida et al 271 
reported expression in 56 of 120 (46.7%) patients with stage II and III colon cancer [8]. 272 
Imaizumi et al reported expression in 112 of 268 (41.8%) patients with stage 0-IV CRC [10]. 273 
In the largest study previously reported, Kang et al reported strong positive staining in 298 of 274 
486 patients with stage I-III colon cancer (61.3%) [9]. Our finding that AQP1 promoter 275 
methylation was associated with decreased transcript expression provides an explanation for 276 
the lack of expression in a significant proportion of CRC. 277 
 278 
The clinical significance of AQP1 protein expression in CRC has yielded conflicting results. 279 
Yoshida et al reported that expression was associated with decreased OS and multivariable 280 
analysis suggested that AQP1 expression was an independent prognostic risk factor (Risk 281 
Ratio 2.593, 95% CI 1.057-6.439, P = 0.038) [8]. The multivariable model consisted of the 282 
confounders age (≥ 75 years), site of primary, presence of bowel obstruction, depth of 283 
invasion, lymph node involvement, and elevated carcinoembryonic antigen. Expression was 284 
more common in left compared to right-sided tumours and was associated with lymph node 285 
involvement, lymphovascular and vascular invasion. More recently, Imaizumi et al reported 286 
that expression was associated with increased depth of invasion, lymph node metastasis, 287 
lymphatic invasion, and venous invasion [10]. Positive expression was more common in left 288 
compared to right-sided tumours, and in moderately compared to well differentiated tumours. 289 
They did not report on OS. Expression was not associated with disease-free survival (DFS) in 290 
patients with stage II and III CRC following surgery with curative intent. Interestingly, 291 
amongst the 84 patients with stage II and III disease that received adjuvant chemotherapy, 292 
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low AQP1 expression was associated with decreased DFS (HR 0.45, 95% CI 0.21-1.00, P = 293 
0.05). In contrast to the other studies, Kang et el reported that strong positivity was associated 294 
with decreased lymph node metastasis [9]. They did not report on expression by side. 295 
Expression did not correlate with either OS or DFS.  296 
 297 
The reasons for the conflicting results between previous studies assessing protein expression 298 
are uncertain. It may be due to the lack of standardisation between studies. The 299 
immunohistochemical staining protocol varied between studies. Each study used a different 300 
anti-AQP1 antibody and it was not clear if the antibodies had been validated. Different 301 
antigen retrieval protocols were used. The definition of AQP1-positivity and the scoring 302 
protocol varied between studies. Membranous and cytoplasmic staining of tumour cells was 303 
assessed in two studies [9, 10], but it was not defined in the other study [8]. These differences 304 
make direct comparisons between the studies and interpretation of the results difficult. 305 
 306 
Previous studies suggest that AQP1 promotes tumour progression by enhancing cancer cell 307 
migration and metastasis, and by increasing endothelial migration and microvessel density 308 
(reviewed in [6]). In vitro studies have demonstrated that knockdown of AQP1 reduced 309 
viability, migration and invasion and promoted apoptosis in ovarian cancer cells [23], 310 
induced apoptosis and inhibited proliferation, adhesion and invasion in osteosarcoma cells 311 
[24], significantly decreased migration and invasion of lung cancer cells [25], reduced the 312 
migration capacity of melanoma [26], colon cancer [27], and endothelial cells [26]. 313 
Overexpression of AQP1 has been shown to accelerate cell migration in vitro [7, 27]. In vivo 314 
studies have demonstrated that overexpression of AQP1 in colon cancer cells increased 315 
pulmonary extravasation in a metastatic murine model [27]. AQP1 knockdown by 316 
intratumoural injection of siRNA reduced tumour volume and microvessel density in a 317 
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murine melanoma model [28]. Furthermore, AQP1 knockout mice developed smaller 318 
tumours with reduced microvessel density and fewer metastases compared to wildtype mice 319 
[7, 29].  320 
 321 
The mechanisms leading to AQP1 promoter methylation in CRC are currently unclear. 322 
Mutations in BRAF are known to alter its kinase activity and subsequently impact on the 323 
activation of mitogen-activated protein pathway [30]. In melanoma, BRAFV600E mutation was 324 
associated with an increase in AQP1 expression, and increased expression was associated 325 
with decreased progression-free and overall survival [31]. In CRC, BRAFV600E mutation was 326 
associated with a high CpG island methylator phenotype (H-CIMP) [32, 33]. However, we 327 
did not find a consistent association between BRAFV600E mutation and AQP1 promoter 328 
hypermethylation in CRC tissues and colon cancer cell lines. In CRC tissues, methylation of 329 
only one probeset, located at +1653 bp from the TSS, was significantly higher in tumours 330 
that harboured a BRAFV600E mutation compared to wildtype. In contrast, BRAFV600E colon 331 
cancer cell lines typically had lower AQP1 promoter methylation and expressed higher levels 332 
of AQP1 transcript compared to wildtype. Together, this suggests that a BRAFV600E mutation 333 
alone does not explain aberrant AQP1 promoter methylation. 334 
 335 
In conclusion, AQP1 transcript expression was significantly decreased in CRC compared to 336 
normal colonic mucosa. Reduced expression was associated with AQP1 promoter 337 
hypermethylation and an increase in overall survival with univariate but not multivariable 338 
analysis. The BRAFV600E mutation did not appear to explain the aberrant AQP1 promoter 339 
methylation. 340 
 341 
MATERIALS AND METHODS 342 
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In silico data 343 
For tissues, RNA sequencing expression (median number of fragments per kilobase of exon 344 
per million reads, FPKM), Infinium HumanMethylation450 BeadChip (HM450) DNA 345 
methylation (beta-values), and BRAF mutation data were obtained from TCGA Research 346 
Network (http://cancergenome.nih.gov/). Expression data were available for a total of 597 347 
CRC patients deposited in the combined TCGA-COAD (n = 438) and TCGA-READ (n = 348 
159) datasets. Of these, seven samples were excluded because the site of primary diagnosis 349 
could not be confirmed as CRC; for four samples the site was not recorded, two were coded 350 
as malignant neoplasm of the connective and soft tissue of abdomen, and one was coded as 351 
malignant (primary) neoplasm, unspecified. A total of 590 CRC patients had AQP1 transcript 352 
expression data for subsequent analyses (Additional file 1: Table S1).  353 
 354 
For the NCI60 cancer cell lines, microarray gene expression were downloaded from Gene 355 
Expression Omnibus (GEO) Datasets using accession numbers GSE32474 [34] and GSE2003 356 
[35]. HM450 data for the NCI60 were downloaded using GEO Datasets accession number 357 
GSE49143. BRAF mutation data were obtained COSMIC (http://cancer.sanger.ac.uk/cosmic) 358 
[19]. 359 
 360 
For the RNA-Seq transcriptomic profiles generated from 5-aza-deoxycytidine treated HT-29 361 
colon cancer cells, data were downloaded from GEO using the accession number GSE41586 362 
[18]. 363 
 364 
Cell lines 365 
Colon cancer cell lines were obtained from American Type Culture Collection (ATCC, 366 
Manassas, VA, USA). Cell lines were maintained in either RPMI-1640 (COLO 205) or 367 
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DMEM (HT-29 and HCT 116) supplemented with 10% foetal bovine serum, 1x Glutamax, 368 
200 U/mL penicillin, and 200 mg/mL streptomycin (Thermo Fisher Scientific, Waltham, 369 
MA, USA) at 37oC in a humidified incubator with 5% CO2 in air.  370 
 371 
Treatment with 5-aza-2’-deoxycytidine 372 
To study the effects of the global demethylating agent 5-aza-2’-deoxycytidine (5-aza-dC), 2.5 373 
x 104 cells were seeded into triplicate wells of a 6-well plate. The following day, the media 374 
were replaced with fresh media supplemented with either 0, 1, 5 or 10 µM 5-aza-dC (Sigma-375 
Aldrich, St Louis, MO, USA), as described previously [36, 37, 38], and the cells were treated 376 
for five days. 377 
 378 
Analysis of AQP1 expression by quantitative PCR 379 
Total RNA was isolated using the PureLink RNA Mini Kit (Thermo Fisher Scientific), and 380 
200 ng was reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, 381 
Hercules, CA, USA) in a final volume of 20 µL. Transcript expression was determined using 382 
duplex TaqMan Gene Expression Assays for AQP1 (Hs01028916_m1) and phosphomannose 383 
mutase 1 (PMM1; Hs00963625_m1; Thermo Fisher Scientific) using Sso Advanced 384 
Universal Probes Supermix (Bio-Rad Laboratories) as described previously [39], using a 385 
ViiA7 Real-Time PCR System (Thermo Fisher Scientific). Results were calculated using the 386 
comparative CT method for relative quantitation (2-CT). 387 
 388 
Statistical analysis 389 
Patients were stratified into high or low AQP1 transcript expression using the best separation 390 
of the combined TCGA RNA sequencing expression data. To choose the best FPKM cut-off 391 
for grouping the patients most significantly, all FPKM values from the 20th to 80th 392 
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percentiles were used to group the patients, significant differences in the survival outcomes 393 
of the groups were examined by Kaplan-Meier survival estimators and the value yielding the 394 
lowest log-rank P value was selected. The prognosis of each group of patients was examined, 395 
and the survival outcomes of the two groups were compared by the log-rank test using Prism 396 
v7.0d for Mac OS X (GraphPad Software, Inc. La Jolla, CA, USA). 397 
 398 
The association between AQP1 expression and overall survival was assessed using Cox 399 
Proportional Hazards models. Unadjusted hazard ratios are reported along with the hazard 400 
ratio adjusted for other significant and independent predictors of survival (age and stage). 401 
The analysis included all 453 patients with complete data on the outcome and predictor 402 
variables. All tests were two-tailed and assessed at the 5% alpha level. The analyses were 403 
conducted using SAS v9.4 (SAS Institute Inc., Cary, NC, USA).  404 
 405 
Comparisons of methylation (beta-values) between groups for individual probesets were 406 
assessed using unpaired Welch’s t-test. Correlations between AQP1 expression and 407 
methylation in CRC were assessed using the Spearman correlation coefficient. P values were 408 
adjusted for multiple comparisons using the Bonferroni correction. Comparison between 409 
relative quantitation of AQP1 transcript expression between cell lines and in response to 5-410 
aza-dC treatment was determined using unpaired t-test and one-way analysis of variance with 411 
Dunnett’s multiple comparisons test. All tests were two-tailed and assessed at the 5% alpha 412 
level. The analyses were conducted using Prism v7.0d for Mac OS X. 413 
 414 
LIST OF ABBREVIATIONS 415 
AQP1: aquaporin-1; bp: base pairs; COSMIC: Catalogue of Somatic Mutation in Cancer 416 
database; CRC: colorectal carcinoma; DFS: disease-free survival; FPKM: fragments per 417 
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kilobase of exon per million reads; GEO: Gene Expression Omnibus; H-CIMP: high CpG 418 
island methylator phenotype; HM450: Infinium HumanMethylation450 BeadChip; HR: 419 
hazard ratio; IQR: interquartile range; NCI60: National Cancer Institute’s 60 human tumour 420 
cell lines; NOS: not otherwise specified; NR: not recorded; ns: not significant; OS: overall 421 
survival; TCGA: The Cancer Genome Atlas; TCGA-COAD: The Cancer Genome Atlas 422 
colorectal adenocarcinoma; TCGA-READ: The Cancer Genome Atlas rectal 423 
adenocarcinoma; TSS: transcription start site. 424 
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 600 
FIGURE LEGENDS 601 
Figure 1: High expression of AQP1 was associated with shorter overall survival in 602 
colorectal carcinoma. RNA sequencing data reported as median number of fragments per 603 
kilobase of exon per million reads (FPKM) and survival data for the 590 patients in the 604 
combined TCGA-COAD and TCGA-READ datasets were obtained from TCGA Research 605 
Network (http://cancergenome.nih.gov/). Low AQP1 transcript expression (n = 261) was 606 
defined as FPKM < 11.4, and high (n = 329) as FPKM ≥ 11.4.  607 
 608 
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Figure 2: Methylation of AQP1 in normal mucosa and colorectal carcinoma from 609 
patients in the combined TCGA-COAD and TCGA-READ datasets. Average beta-values 610 
for all available individual probesets located in the region -500 to +500 bp from the AQP1 611 
transcription start site (TSS) for normal mucosa (N, n= 32) and colorectal carcinoma (CRC, n 612 
= 317). Differential methylation (deltaBeta) was calculated by subtracting the average beta-613 
value of N from CRC. Comparisons between N and CRC were considered statistically 614 
significant when the adjusted P value (adj. P) for the unpaired Welch’s t-test with Bonferroni 615 
correction for multiple comparisons was < 0.05. * adj. P < 0.05. 616 
 617 
Figure 3: Methylation of AQP1 in low and high AQP1 expressing colorectal carcinoma 618 
from patients in the combined TCGA-COAD and TCGA-READ datasets. Average beta-619 
values for all available individual probesets located in the region -500 to +500 bp from the 620 
AQP1 transcription start site (TSS) for AQP1 low (n = 127) and high (n = 190) expressing 621 
colorectal carcinoma. Differential methylation (deltaBeta) was calculated by subtracting the 622 
average beta-value of AQP1 high from AQP1 low expressing CRC. Comparisons between 623 
AQP1 low and AQP1 high were considered statistically significant when the adjusted P value 624 
(adj. P) for the unpaired Welch’s t-test with Bonferroni correction for multiple comparisons 625 
was < 0.05. * adj. P < 0.05. 626 
 627 
Figure 4: Low AQP1 expression was associated with increased promoter methylation in 628 
the NCI60 colon cancer cell lines. a) AQP1 transcript expression in colon cancer cell lines 629 
from the NCI60 panel. Microarray gene expression data for the NCI60 panel were 630 
downloaded from Gene Expression Omnibus Datasets (GEO) using accession numbers 631 
GSE32474 and GSE2003, and log2 data were expressed relative to the expression in COLO 632 
205. Data for GSE32474 are the average of triplicate microarrays. b) Relative quantitation of 633 
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AQP1 transcript expression was determined by the comparative CT method (2-CT) in colon 634 
cancer cell lines using duplex TaqMan Gene Expression Assays, with PMM1 as endogenous 635 
control. Data are relative to COLO 205. Each data point is the average of triplicate reactions 636 
for three biological replicates, with bars representing the mean with standard deviation. c) 637 
AQP1 methylation in colon cancer cell lines from the NCI60 panel. Beta-values were 638 
downloaded using GEO accession number GSE49143. Average beta-values were calculated 639 
for the low (HCT 15, KM12, SW620 and HCT 116) and the high to moderate (high/mod.) 640 
AQP1 expressing colon cancer cell lines (COLO 205, HT-29, HCC2998). Differential 641 
methylation (deltaBeta) was calculated by subtracting the average beta-value of the 642 
high/mod. from the low expressing cell lines. Comparisons between low and high/mod. were 643 
considered statistically significant when the P value for the unpaired Welch’s t-test was < 644 
0.05. * P < 0.05. d) RNA-Seq data for HT-29 treated with 0, 5 or 10 µM 5-aza-dC for five 645 
days were downloaded using accession number GSE41586. Data are the mean with standard 646 
deviation of three biological replicates, expressed relative 0 µM 5-aza-dC. e) Relative 647 
quantitation of AQP1 transcript expression in COLO 205, HT-29 and HCT 116 following 648 
five days of treatment with 5-aza-dC. Data are the mean with standard deviation of three 649 
biological replicates, expressed relative 0 µM 5-aza-dC.  650 
 651 
Figure 5: AQP1 methylation in colorectal carcinoma tissues and cell lines according to 652 
BRAFV600E mutation status. Average beta-values for all individual probesets located in the 653 
region from -5,000 to +25,000 bp of the AQP1 transcription start site (TSS) for a) TCGA 654 
CRC tissues, and b) the NCI60 panel of cell lines. Differential methylation (deltaBeta) was 655 
calculated by subtracting the average beta-value of samples with wildtype from samples with 656 




Table 1. AQP1 transcript expression in tissues from the combined TCGA-COAD and 660 
TCGA-READ datasets by clinicopathological characteristics 661 
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  < 50 
  ≥ 50 ≤ 65 
  > 65 
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Lymph node metastasis 
  No (stage I-II) 
















Site of primary2 












  Left 











  Adenocarcinoma, NOS 
  Mucinous adenocarcinoma 





















  Wildtype 
  BRAFV600E mutation 





















1Comparison to stage IV.  662 
2Right-sided CRC was defined as caecum, ascending, hepatic flexure and transverse colon 663 
and left-sided as splenic flexure, descending, sigmoid, rectosigmoid and rectum. 664 
NR, not recorded 665 
NOS, not otherwise specified 666 
 667 
Table 2. Overall survival for the 453 patients with complete clinical data in the 668 
combined TCGA-COAD and TCGA-READ datasets 669 
 Univariate Multivariable 
 HR (95% CI) P value HR (95% CI) P value 
AQP1 expression 
  Low 













Age 1.03 (1.01-1.04) 0.003 1.04 (1.02-1.06) < 0.0001 
Stage     
 30 
  I-II 
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  Female 








Site of primary 
  Left 









  Adenocarcinoma, NOS 










  Wildtype 

















Figure S1: Methylation of AQP1 in normal mucosa and colorectal carcinoma from 
patients in the combined TCGA-COAD and TCGA-READ datasets. Average beta-values 
for all available individual probesets, located within the region -5,000 bp upstream and 
+25,000 bp downstream of the AQP1 transcription start site (TSS), for normal mucosa (N, n 
= 32) and colorectal carcinoma (CRC, n = 317). Differential methylation (deltaBeta) was 





Figure S2: Methylation of individual probesets for normal mucosa and colorectal 
carcinoma from patients in the combined TCGA-COAD and TCGA-READ datasets. 
Beta-values for colorectal carcinoma (CRC, n = 317) and normal mucosa (N, n = 32) for all 
individual probesets located in the region from -5,000 to +25,000 bp of the AQP1 
transcription start site. Horizontal bars represent average beta-value for either N or CRC. 
Comparison between N and CRC were considered statistically significant when the adjusted 
P value (adj. P) for the unpaired Welch’s t-test with Bonferroni correction for multiple 




Figure S3: Correlations between AQP1 transcript expression and promoter 
methylation. RNAseq expression data reported as median number of fragments per kilobase 
of exon per million reads (FPKM) and HM450 methylation data reported as beta-values for 
all individual probesets located in the region from -5,000 to +25,000 bp of the AQP1 
transcription start site. Expression and methylation data were available for 317 CRC. 
Correlations between expression and methylation were considered statistically significant 
when the adjusted P value (adj. P) for the Spearman correlation coefficient (r) with 




Figure S4: Methylation of individual probesets in low and high AQP1 expressing 
colorectal carcinoma from patients in the combined TCGA-COAD and TCGA-READ 
datasets. Beta-values for AQP1 low (n = 127) and high (n = 190) expressing CRC for all 
individual probesets located in the region from -5,000 to +25,000 bp of the AQP1 
transcription start site. Horizontal bars represent average beta-value for either AQP1 low or 
high expressing CRC. Comparison between AQP1 low and high were considered statistically 
significant when the adjusted P value (adj. P) for the unpaired Welch’s t-test with Bonferroni 




Figure S5: Methylation of individual probesets for colon cancer cell lines in the NCI60 
panel. Cell lines were stratified on the basis of AQP1 expression, with COLO-205, HT-29, 
and HCC2998 defined as high to moderate (H/M), and HCT 15, KM12, SW620 and HCT 
116 as low (L). Horizontal bars represent average beta-value for either AQP1 H/M or L 
expressing CRC. Comparisons between H/M and L AQP1 expressing cell lines were 
considered statistically significant when the P value for the Welch’s unpaired t-test was < 




Figure S6: Methylation of individual probesets for colorectal carcinoma from the 
combined TCGA-COAD and TCGA-READ datasets with either wildtype or BRAFV600E 
mutation. Beta-values for all individual probesets located in the region from -5,000 to 
+25,000 bp of the AQP1 transcription start site, and BRAF mutation status for the 
corresponding sample were obtained from TCGA Research Network 
(http://cancergenome.nih.gov/). Horizontal bars represent the average beta-value for either 
wildtype (WT) or BRAFV600E mutation (V600E). Comparisons between WT and V600E were 
considered statistically significant when the adjusted P value (adj. P) for the unpaired 





Figure S7: Methylation of individual probesets for cell lines in the NCI60 panel with 
either wildtype or BRAFV600E mutation. Beta-values for all individual probesets located in 
the region from -5,000 to +25,000 bp of the AQP1 transcription start site were analysed in the 
GEO Dataset GSE49143. BRAF mutation status for each of the cell lines was obtained from 
COSMIC (http://cancer.sanger.ac.uk/cosmic). Horizontal bars represent the average beta-
value for either wildtype (WT) or BRAFV600E mutation (V600E). Comparisons between WT 
and V600E were considered statistically significant when the adjusted P value (adj. P) for the 
 2 
unpaired Welch’s t-test with Bonferroni correction for multiple comparisons was < 0.05. ns, 
not significant. 
 1 
Table S1: Clinicopathological features of the 590 colorectal carcinoma patients from the 
combined TCGA-COAD and TCGA-READ datasets. 
 
Feature Number % 
All CRC 590 100 
Gender 
  Female 








  < 50 
  ≥ 50 ≤ 65 
  > 65 












  I 
  II 
  III 
  IV 













Site of primary 
  Right-sided 
  Left-sided 
  Rectum 












  Mucinous adenocarcinoma (8480/3) 
  Adenocarcinoma, NOS (8140/3) 
  Adenocarcinoma in tubulovillous adenoma (8263/3) 
  Tubular adenocarcinoma (8211/3) 
  Papillary adenocarcinoma, NOS (8260/3) 
  Adenocarcinoma with mixed subtypes (8255/3) 
  Carcinoma, NOS (8010/3) 
  Adenosquamous carcinoma (8560/3) 





















NR, not recorded 
NOS, not otherwise specified 
 1 
Table S2: Analysis of AQP1 transcript expression in normal colonic mucosa, adenoma, and colorectal carcinoma from publicly available 






Normal tissue median 
expression (range)1 










3.684 (1.968 to 7.802) Rectal 
adenocarcinoma 
(n=65) 
2.606 (-0.126 to 4.831) -2.341 5.13 x 10-14 
Skrzypczak et 




3.806 (2.742 to 4.692) Adenoma epithelia, 
microdissected 
(n=5) 




4.36 x 10-10 
 








5.38 x 10-9 
 





3.202 (1.118 to 3.6) Adenoma epithelia 
and lamina propria, 
microdissected 
(n=5) 




4.11 x 10-8 
 





1.881 (1.426 to 2.046) 
 
-2.196 7.26 x 10-4 
 Normal mucosa 
(n=24)  
4.045 (2.325 to 6.209) Colorectal 
adenocarcinoma 
(n=45) 
2.299 (0.634 to 6.089) -3.259 2.49 x 10-9 
   Colorectal 
carcinoma (n=36) 
3.236 (1.706 to 5.292) -1.660 0.002 
 2 




2.931 (1.906 to 3.585) Colorectal 
carcinoma (n=70) 
2.77 (0.419 to 5.199) -1.100 0.241 




-0.846 (-1.295 to 1.117) Colorectal 
adenoma epithelia 
(n=56) 
-1.198 (-2.161 to 0.135) -1.366 0.002 
Sabates-Bellver 
et al, 2007 (27) 
Normal mucosa 
(n=32) 
3.492 (2.192 to 4.222) Colon adenoma 
(n=25) 
1.715 (-0.892 to 3.342) -3.565 4.08 x 10-11 
   Rectal adenoma 
(n=7) 
0.708 (-2.897 to 3.966) -5.687 0.009 




1.502 (0.351 to 3.513) Colon 
adenocarcinoma 
(n=77) 
1.271 (-0.009 to 5.03) -1.264 0.012 




1.95 (1.593 to 2.133) Caecum 
adenocarcinoma 
(n=17) 
1.541 (0.637 to 3.698) -1.276 0.051 




2.092 (1.303 to 3.245) Colon carcinoma 
(n=9) 
3.345 (1.22 to 4.154) 1.877 0.014 
   Colon 
adenocarcinoma 
(n=41) 
1.503 (0.114 to 3.698) -1.202 0.063 
   Colon mucinous 
adenocarcinoma 
(n=13) 
1.878 (0.303 to 2.765) -1.116 0.236 
   Rectal 
adenocarcinoma 
(n=8) 
2.151 (0.185 to 2.866) -1.212 0.246 
   Rectosigmoid 
adenocarcinoma 
(n=10) 
2.078 (1.479 to 3.469) 1.111 0.761 
   Rectal mucinous 
adenocarcinoma 
(n=4) 
3.296 (1.797 to 3.39) 2.035 0.036 
 3 
Notterman et 
al, 2001 (28) 
Normal mucosa 
(n=18) 
2.338 (1.07 to 2.844) Colon 
adenocarcinoma 
(n=18) 
1.892 (0.628 to 2.722) -1.374 0.006 




-0.217 (-1.753 to 0.610) Colon 
adenocarcinoma 
(n=40) 
-0.392 (-2.689 to 0.907) -1.149 0.120 
1Expression of AQP1 reported as log2 median-centred intensity. 
